{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Cancer&page=2", "query": { "condition": "Advanced Gastrointestinal Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T22:52:26.166Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Cancer", "Melanoma", "Non-Small-Cell Lung Cancer", "Hepatocellular Cancer", "Bladder Cancer", "Sarcoma", "Head and Neck Cancer", "Colorectal Cancer", "Ovarian Cancer", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "PF-07263689", "type": "BIOLOGICAL" }, { "name": "Sasanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-10-20", "completion_date": "2022-10-14", "has_results": true, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061537" }, { "nct_id": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Colorectal Cancer", "Cervical Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2013-12-19", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975831" }, { "nct_id": "NCT04106856", "title": "Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Locally Advanced Unresectable Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-08-08", "completion_date": "2026-02-17", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106856" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" }, { "nct_id": "NCT06466187", "title": "A Study of SGN-MesoC2 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Ovarian Neoplasms", "Pancreatic Adenocarcinoma", "Colorectal Neoplasms", "Mesothelioma", "Other Solid Tumors", "Endometrial" ], "interventions": [ { "name": "PF-08052666", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2024-08-02", "completion_date": "2026-05-27", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06466187" }, { "nct_id": "NCT03427814", "title": "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Inoperable Gastric Cancer" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2018-07-03", "completion_date": "2023-01-03", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 7, "location_summary": "Miami, Florida • West Palm Beach, Florida • Goshen, Indiana + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03427814" }, { "nct_id": "NCT07189871", "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Cancer (CRPC)", "Colorectal Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "TNBC, Triple Negative Breast Cancer", "Small Cell Lung Cancer (SCLC )", "Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "177Lu-BetaBart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2026-02-23", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 4, "location_summary": "Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07189871" }, { "nct_id": "NCT06194877", "title": "A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Pancreatic Ductal Cancer", "Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers" ], "interventions": [ { "name": "BGB-3245", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MapKure, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2024-04-18", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 3, "location_summary": "Duarte, California • Durham, North Carolina • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06194877" }, { "nct_id": "NCT02112162", "title": "Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Neoplasms" ], "interventions": [ { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "DEVICE" }, { "name": "magnetic resonance imaging", "type": "DEVICE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-06", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112162" }, { "nct_id": "NCT00471146", "title": "Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "AG-013736", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2007-07", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-07-16", "last_synced_at": "2026-09-23T22:52:26.166Z", "location_count": 77, "location_summary": "Antioch, California • Corona, California • Glendora, California + 57 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00471146" } ] }